Cite
HARVARD Citation
Patel, M. et al. (n.d.). 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. Journal for immunotherapy of cancer. p. A193. [Online].